Cargando…
Screening for Preeclampsia and Fetal Growth Restriction in the First Trimester in Women without Chronic Hypertension
Background: Nowadays, it is possible to identify a group at increased risk of preeclampsia (PE) and fetal growth restriction (FGR) using the principles of the Fetal Medicine Foundation (FMF). It has been established for several years that acetylsalicylic acid (ASA) reduces the incidence of PE and FG...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488103/ https://www.ncbi.nlm.nih.gov/pubmed/37685649 http://dx.doi.org/10.3390/jcm12175582 |
_version_ | 1785103399299055616 |
---|---|
author | Tousty, Piotr Fraszczyk-Tousty, Magda Golara, Anna Zahorowska, Adrianna Sławiński, Michał Dzidek, Sylwia Jasiak-Jóźwik, Hanna Nawceniak-Balczerska, Magda Kordek, Agnieszka Kwiatkowska, Ewa Cymbaluk-Płoska, Aneta Torbé, Andrzej Kwiatkowski, Sebastian |
author_facet | Tousty, Piotr Fraszczyk-Tousty, Magda Golara, Anna Zahorowska, Adrianna Sławiński, Michał Dzidek, Sylwia Jasiak-Jóźwik, Hanna Nawceniak-Balczerska, Magda Kordek, Agnieszka Kwiatkowska, Ewa Cymbaluk-Płoska, Aneta Torbé, Andrzej Kwiatkowski, Sebastian |
author_sort | Tousty, Piotr |
collection | PubMed |
description | Background: Nowadays, it is possible to identify a group at increased risk of preeclampsia (PE) and fetal growth restriction (FGR) using the principles of the Fetal Medicine Foundation (FMF). It has been established for several years that acetylsalicylic acid (ASA) reduces the incidence of PE and FGR in high-risk populations. This study aimed to evaluate the implementation of ASA use after the first-trimester screening in a Polish population without chronic hypertension, as well as its impact on perinatal complications. Material and methods: A total of 874 patients were enrolled in the study during the first-trimester ultrasound examination. The risk of PE and FGR was assessed according to the FMF guidelines, which include the maternal history, mean arterial pressure (MAP), uterine artery pulsatility index (UtPI), pregnancy-associated plasma protein A (PAPP-A) and placental growth factor (PLGF). Among patients with a risk higher than >1:100, ASA was administered at a dose of 150 mg. Perinatal outcomes were assessed among the different groups. Results: When comparing women in the high-risk group with those in the low-risk group, a statistically significantly higher risk of pregnancy complications was observed in the high-risk group. These complications included pregnancy-induced hypertension (PIH) (OR 3.6 (1.9–7)), any PE (OR 7.8 (3–20)), late-onset PE (OR 8.5 (3.3–22.4)), FGR or small for gestational age (SGA) (OR 4.8 (2.5–9.2)), and gestational diabetes mellitus type 1 (GDM1) (OR 2.4 (1.4–4.2)). The pregnancies in the high-risk group were more likely to end with a cesarean section (OR 1.9 (1.2–3.1)), while the newborns had significantly lower weights (<10 pc (OR 2.9 (1.2–6.9)), <3 pc (OR 10.2 (2.5–41.7))). Conclusions: The first-trimester screening test for PE and FGR is a necessary and effective tool in identifying high-risk pregnancies. ASA prophylaxis among high-risk patients may have the most beneficial effect. Furthermore, this screening tool may significantly reduce the incidence of early-onset PE (eo-PE). |
format | Online Article Text |
id | pubmed-10488103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104881032023-09-09 Screening for Preeclampsia and Fetal Growth Restriction in the First Trimester in Women without Chronic Hypertension Tousty, Piotr Fraszczyk-Tousty, Magda Golara, Anna Zahorowska, Adrianna Sławiński, Michał Dzidek, Sylwia Jasiak-Jóźwik, Hanna Nawceniak-Balczerska, Magda Kordek, Agnieszka Kwiatkowska, Ewa Cymbaluk-Płoska, Aneta Torbé, Andrzej Kwiatkowski, Sebastian J Clin Med Article Background: Nowadays, it is possible to identify a group at increased risk of preeclampsia (PE) and fetal growth restriction (FGR) using the principles of the Fetal Medicine Foundation (FMF). It has been established for several years that acetylsalicylic acid (ASA) reduces the incidence of PE and FGR in high-risk populations. This study aimed to evaluate the implementation of ASA use after the first-trimester screening in a Polish population without chronic hypertension, as well as its impact on perinatal complications. Material and methods: A total of 874 patients were enrolled in the study during the first-trimester ultrasound examination. The risk of PE and FGR was assessed according to the FMF guidelines, which include the maternal history, mean arterial pressure (MAP), uterine artery pulsatility index (UtPI), pregnancy-associated plasma protein A (PAPP-A) and placental growth factor (PLGF). Among patients with a risk higher than >1:100, ASA was administered at a dose of 150 mg. Perinatal outcomes were assessed among the different groups. Results: When comparing women in the high-risk group with those in the low-risk group, a statistically significantly higher risk of pregnancy complications was observed in the high-risk group. These complications included pregnancy-induced hypertension (PIH) (OR 3.6 (1.9–7)), any PE (OR 7.8 (3–20)), late-onset PE (OR 8.5 (3.3–22.4)), FGR or small for gestational age (SGA) (OR 4.8 (2.5–9.2)), and gestational diabetes mellitus type 1 (GDM1) (OR 2.4 (1.4–4.2)). The pregnancies in the high-risk group were more likely to end with a cesarean section (OR 1.9 (1.2–3.1)), while the newborns had significantly lower weights (<10 pc (OR 2.9 (1.2–6.9)), <3 pc (OR 10.2 (2.5–41.7))). Conclusions: The first-trimester screening test for PE and FGR is a necessary and effective tool in identifying high-risk pregnancies. ASA prophylaxis among high-risk patients may have the most beneficial effect. Furthermore, this screening tool may significantly reduce the incidence of early-onset PE (eo-PE). MDPI 2023-08-27 /pmc/articles/PMC10488103/ /pubmed/37685649 http://dx.doi.org/10.3390/jcm12175582 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tousty, Piotr Fraszczyk-Tousty, Magda Golara, Anna Zahorowska, Adrianna Sławiński, Michał Dzidek, Sylwia Jasiak-Jóźwik, Hanna Nawceniak-Balczerska, Magda Kordek, Agnieszka Kwiatkowska, Ewa Cymbaluk-Płoska, Aneta Torbé, Andrzej Kwiatkowski, Sebastian Screening for Preeclampsia and Fetal Growth Restriction in the First Trimester in Women without Chronic Hypertension |
title | Screening for Preeclampsia and Fetal Growth Restriction in the First Trimester in Women without Chronic Hypertension |
title_full | Screening for Preeclampsia and Fetal Growth Restriction in the First Trimester in Women without Chronic Hypertension |
title_fullStr | Screening for Preeclampsia and Fetal Growth Restriction in the First Trimester in Women without Chronic Hypertension |
title_full_unstemmed | Screening for Preeclampsia and Fetal Growth Restriction in the First Trimester in Women without Chronic Hypertension |
title_short | Screening for Preeclampsia and Fetal Growth Restriction in the First Trimester in Women without Chronic Hypertension |
title_sort | screening for preeclampsia and fetal growth restriction in the first trimester in women without chronic hypertension |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488103/ https://www.ncbi.nlm.nih.gov/pubmed/37685649 http://dx.doi.org/10.3390/jcm12175582 |
work_keys_str_mv | AT toustypiotr screeningforpreeclampsiaandfetalgrowthrestrictioninthefirsttrimesterinwomenwithoutchronichypertension AT fraszczyktoustymagda screeningforpreeclampsiaandfetalgrowthrestrictioninthefirsttrimesterinwomenwithoutchronichypertension AT golaraanna screeningforpreeclampsiaandfetalgrowthrestrictioninthefirsttrimesterinwomenwithoutchronichypertension AT zahorowskaadrianna screeningforpreeclampsiaandfetalgrowthrestrictioninthefirsttrimesterinwomenwithoutchronichypertension AT sławinskimichał screeningforpreeclampsiaandfetalgrowthrestrictioninthefirsttrimesterinwomenwithoutchronichypertension AT dzideksylwia screeningforpreeclampsiaandfetalgrowthrestrictioninthefirsttrimesterinwomenwithoutchronichypertension AT jasiakjozwikhanna screeningforpreeclampsiaandfetalgrowthrestrictioninthefirsttrimesterinwomenwithoutchronichypertension AT nawceniakbalczerskamagda screeningforpreeclampsiaandfetalgrowthrestrictioninthefirsttrimesterinwomenwithoutchronichypertension AT kordekagnieszka screeningforpreeclampsiaandfetalgrowthrestrictioninthefirsttrimesterinwomenwithoutchronichypertension AT kwiatkowskaewa screeningforpreeclampsiaandfetalgrowthrestrictioninthefirsttrimesterinwomenwithoutchronichypertension AT cymbalukpłoskaaneta screeningforpreeclampsiaandfetalgrowthrestrictioninthefirsttrimesterinwomenwithoutchronichypertension AT torbeandrzej screeningforpreeclampsiaandfetalgrowthrestrictioninthefirsttrimesterinwomenwithoutchronichypertension AT kwiatkowskisebastian screeningforpreeclampsiaandfetalgrowthrestrictioninthefirsttrimesterinwomenwithoutchronichypertension |